NCT06287593View on ClinicalTrials.gov

The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC

NANot yet recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

EGF-R Positive Non-Small Cell Lung Cancer

Interventions

OTHER

ctDNA monitoring

Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.

All Listed Sponsors

lead

Zhejiang University

OTHER

NCT06287593 - The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC | Biotech Hunter | Biotech Hunter